MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Intraperitoneal Chemotherapy

Abdominal Wall Morbidity Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

Scandinavian Journal of Surgery 2017 March [Epub ahead of print] [Link] Struller F, Koenigsrainer I, Horvath P, Koenigsrainer A, Beckert S Abstract BACKGROUND: Incisional hernia formation has been reported as high as 20% within 1 year following midline laparotomy. Since hyperthermic intraperitoneal chemotherapy is likely to impair wound healing, we sought to investigate the incidence […]

Comments Off on Abdominal Wall Morbidity Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival

European Journal of Surgical Oncology 2017 Janury 29 [Epub ahead of print] [Link] Sugarbaker PH, Chang D Abstract PURPOSE: Malignant peritoneal mesothelioma (MPM) is a rare disease with about 300 new cases per year in the USA. Its natural history is described as local progression within the peritoneal space in the absence of liver metastases […]

Comments Off on Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival

Mentored experience of establishing a national peritoneal malignancy programme – Experience of first 50 operative cases

European Journal of Surgical Oncology 2016 November [Epub ahead of print] [Link] Chang KH, Kazanowski M, Staunton O, Cahill RA, Moran BJ, Shields C, Mulsow J Abstract BACKGROUND: Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) are considered standard of care for pseudomyxoma peritonei (PMP) and selected patients with colorectal peritoneal metastases (CPM) or peritoneal […]

Comments Off on Mentored experience of establishing a national peritoneal malignancy programme – Experience of first 50 operative cases

Trabectedin is active against malignant pleural mesothelioma cell and xenograft models and synergizes with chemotherapy and bcl-2 inhibition in vitro

Molecular Cancer Therapeutics 2016 August 10 [Epub ahead of print] [Link] Hoda MA, Pirker C, Dong Y, Schelch K, Heffeter P, Kryeziu K, van Schoonhoven S, Klikovits T, Laszlo V, Rozsas A, Ozsvar J, Klepetko W, Doeme B, Grusch M, Hegedues B, Berger W Abstract Malignant pleural mesothelioma (MPM) is characterized by widespread resistance to […]

Comments Off on Trabectedin is active against malignant pleural mesothelioma cell and xenograft models and synergizes with chemotherapy and bcl-2 inhibition in vitro

Preventing recurrence of diffuse malignant peritoneal mesothelioma

Expert Review of Anticancer Therapy 2016 August 3 [Epub ahead of print] [Link] Leinwand JC, Chabot JA, Kluger MD Abstract INTRODUCTION: Diffuse malignant peritoneal mesothelioma (DMPM) is an aggressive malignancy with a poor prognosis when treated with systemic therapy. Cytoreductive surgery (CRS) with intraperitoneal chemotherapy (IPC) is considered the best therapy in DMPM, but a […]

Comments Off on Preventing recurrence of diffuse malignant peritoneal mesothelioma

Treatment of peritoneal surface malignancies with hyperthermic intraperitoneal chemotherapy-current perspectives

Current Oncology 2016 June 23 [Epub June 9] [Link] Spiliotis J, Halkia E, de Bree E. Abstract Peritoneal carcinomatosis (ptc) represents advanced malignant disease and has generally been associated with a grim prognosis. Peritoneal surface malignancy is often the major source of morbidity and mortality; it is of major concern in cancer management. Although ptc […]

Comments Off on Treatment of peritoneal surface malignancies with hyperthermic intraperitoneal chemotherapy-current perspectives

Nanoparticle tumor localization, disruption of autophagosomal trafficking, and prolonged drug delivery improve survival in peritoneal mesothelioma

Biomaterials 2016 June 22 [Epub ahead of print] [Link] Liu R, Colby AH, Gilmore D, Schulz M, Zeng J, Padera RF, Shirihai O, Grinstaff MW, Colson YL Abstract The treatment outcomes for malignant peritoneal mesothelioma are poor and associated with high co-morbidities due to suboptimal drug delivery. Thus, there is an unmet need for new […]

Comments Off on Nanoparticle tumor localization, disruption of autophagosomal trafficking, and prolonged drug delivery improve survival in peritoneal mesothelioma

Pharmacokinetics and the effect of heat on intraperitoneal pemetrexed using a murine model

Surgical Oncology 2016 May 20 [Epub ahead of print] [Link] Badrudin D, Perrault-Mercier C, Bouchard-Fortier A, Hubert J, Leblond FA, Sideris L, Dubé P. Abstract BACKGROUND: Pemetrexed is a systemic chemotherapeutic agent used in the treatment of malignant mesothelioma. This drug represents a potentially promising intraperitoneal (IP) agent to use for hyperthermic intraperitoneal chemotherapy (HIPEC) […]

Comments Off on Pharmacokinetics and the effect of heat on intraperitoneal pemetrexed using a murine model

The role of “closed abdomen” hyperthermic intraperitoneal chemotherapy (HIPEC) in the palliative treatment of neoplastic ascites from peritoneal carcinomatosis: report of a single-center experience.

Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer 2016 May 12 [Epub ahead of print] [Link] Orgiano L, Pani F, Astara G, Madeddu C, Marini S, Manca A, Mantovani G. Abstract PURPOSE: The purpose of this study was to review the results of a single-center experience in the […]

Comments Off on The role of “closed abdomen” hyperthermic intraperitoneal chemotherapy (HIPEC) in the palliative treatment of neoplastic ascites from peritoneal carcinomatosis: report of a single-center experience.

Cytoreductive surgery and intraperitoneal chemotherapy: an evidence-based review-past, present and future

Journal of Gastrointestinal Oncology 2016 February [Link] Dehal A, Smith JJ, Nash GM. Abstract Peritoneal carcinomatosis (PC) has historically been considered a terminal condition with merely palliative treatment achieving a survival rate measured in months. Cytoreductive surgery (CyRS) and intraperitoneal chemotherapy (IPC) have emerged as potentially effective regional treatments with the potential for long-term survival […]

Comments Off on Cytoreductive surgery and intraperitoneal chemotherapy: an evidence-based review-past, present and future